phylogica* for personal use only 2014*agmpresenta7on* … · 2014. 11. 27. · harnessing...
Post on 11-Sep-2020
2 Views
Preview:
TRANSCRIPT
Harnessing biodiversity for peptide therapeutics
Phylogica 2014 AGM Presenta7on
(PYC:ASX)
For
per
sona
l use
onl
y
Disclaimer The purpose of the presenta.on is to provide an update of the business of Phylogica Limited (ASX:PYC) [‘Phylogica’]. These slides have been prepared as a presenta.on aid only and the informa.on they contain may require further explana.on and/or clarifica.on. Accordingly, these slides and the informa.on they contain should be read in conjunc.on with past and future announcements made by Phylogica and should not be relied upon as an independent source of informa.on. Please contact Phylogica and/or refer to the Company's website for further informa.on.
The views expressed in this presenta.on contain informa.on derived from publicly available sources that have not been independently verified. No representa.on or warranty is made as to the accuracy, completeness or reliability of the informa.on.
Any forward looking statements in this presenta.on have been prepared on the basis of a number of assump.ons which may prove incorrect and the current inten.ons, plans, expecta.ons and beliefs about future events are subject to risks, uncertain.es and other factors, many of which are outside Phylogica’s control. Important factors that could cause actual results to differ materially from assump.ons or expecta.ons expressed or implied in this presenta.on include known and unknown risks. Because actual results could differ materially to assump.ons made and Phylogica’s current inten.ons, plans, expecta.ons and beliefs about the future, you are urged to view all forward looking statements contained in this presenta.on with cau.on.
This presenta.on should not be relied on as a recommenda.on or forecast by Phylogica. Nothing in this presenta.on should be construed as either an offer to sell or a solicita.on of an offer to buy or sell shares in any jurisdic.on.
2
For
per
sona
l use
onl
y
3
2014 Highlights
§ Successfully validated powerful intracellular drug delivery plaTorm
§ Iden.fied ‘Best-‐in-‐Class’ Phylomers for delivering drugs inside cells
§ ‘Value-‐adding’ strategy to improve intracellular delivery of exis.ng drugs
§ Launched proprietary cancer programme (Product Focus)
§ Announced collabora.on with Genentech
For
per
sona
l use
onl
y
Corporate Snapshot
4
Shareholders % B. Hockings 25 Sietsma Holdings 8 Bonadido 4 Top 15 55
Execu&ve Team Dr Richard Hopkins – CEO Dr Paul WaQ -‐ CSO
Summary
ASX PYC Cash (9/14) 4.7m Net Burn 3.2m Market Cap 16m 52 wk low/high 0.1/0.4c Shares on issue 1000m
Board of Directors
Dr Doug Wilson Non-‐Execu7ve Chairman
Dr Richard Hopkins CEO
Jeremy Curnock-‐Cook NED
Dr Bernard Hockings NED
Bruce McHarrie NED
For
per
sona
l use
onl
y
Phylogica: focussed on intracellular delivery of biologics
CNS Delivery
Antimicrobials
Vaccines Cell penetrating peptides
5
Intracellular Drug Delivery
Cancer
Differen7a7on Product Focus
For
per
sona
l use
onl
y
Technology Update
For
per
sona
l use
onl
y
Majority of drug targets are inside cells
§ PYC addressing unmet need to deliver biologic drugs inside cells!
Intracellular Drug Targets
Small Molecule Drugs (10%)
Undrugged targets (90%) Biologics?
For
per
sona
l use
onl
y
Pep7des: purpose built for the job
8
Small Molecule Drugs
Large Biologics (Smart drugs)
Size
Targets
Phylomer Pep7des
Cell Penetra7ng
Specific (Biologic)
For
per
sona
l use
onl
y
Cell Penetra7ng Phylomer (CPPs): delivering biologics cargoes inside cells
9
Poten7al to expand the druggable landscape by >10-‐fold!!
For
per
sona
l use
onl
y
Valida7on of ‘Best in Class’ Phylomers for intracellular drug delivery
10
For
per
sona
l use
onl
y
‘Best-‐in-‐class’ Phylomers for delivering drugs inside cells
27/11/14 11
HisMBP
PYC35_R
BD_S11
TAT_RBD_S
11
PYC-FPP-3_
RBD_S11
PYC-FPP-2_
RBD_S11
PYC-FPP-4_
RBD_S11
PYC-FPP-1_
RBD_S11
0
10
20
30
40
50%
gre
en v
iabl
e ce
lls (Q
3)si
ngle
cel
l pop
ulat
ion
10µM protein3µM protein
High receptor-‐expressing cells: transfec.on efficiency: 70.3%
‘Best in Class’ Phylomer CPP
Delivery effi
cien
cy
(% Green
Cells)
25-‐fold
§ Phylomers improve intracellular drug deliver 25-‐50 X § Phylomers are up to 37-‐X befer than previous cell penetra.ng gold standard
For
per
sona
l use
onl
y
Applica7ons for Phylogica’s ‘Best-‐in-‐Class’ Drug Deliver Solu7on
12
For
per
sona
l use
onl
y
Mul7ple commercialis7on opportuni7es
13
Cell Penetra.ng Phylomers
Improve delivery of exis.ng drugs
‘Value Adding’
Plalorm Products
Fully integrated drug delivery/discovery plaTorm
‘Phylomer Therapeu?cs’
For
per
sona
l use
onl
y
Value Adding: Approaching key potency thresholds
14
10 µM
1 µM
0.1 µM
Phylomer CPPs_toxins
<1µM = key potency threshold
Amount of Drug
Increasing Drug Ac
7vity
Phylomer CPPs_cargoes
Standard CPP_Cargoes
Compe7tors
For
per
sona
l use
onl
y
Phylogica’s Oncology Programme
Targe7ng Breat Cancer
15
For
per
sona
l use
onl
y
Developing Phylomer drugs to treat cancer
§ Unmet need for drugs against breast cancer targets intractable to conven.onal therapies
§ Phylogica’s plaTorm accelerates path to drug discovery
§ Rapid access to high-‐value commercial inflexion points
16
For
per
sona
l use
onl
y
Phylogica’s Proprietary Oncology Programme
Program Indica7on Discovery Func7onal Valida7on Preclinical
Stat 5/3 Breast Cancer
Myc Breast Cancer
YB1
Breast Cancer F
or p
erso
nal u
se o
nly
Upcoming commercial milestones
§ Discovery Partnerships – Genentech II (2014/15) – New discovery alliances – Cosmeceu.cal out-‐license (Biolink)
§ Oncology programme – Early 2015: In vitro data – important early-‐stage partnering opportunity.
– Late 2015: In vivo data -‐ Licensing opportunity
18
For
per
sona
l use
onl
y
A Big Thankyou To All PYC Staff!!!!!
19
For
per
sona
l use
onl
y
Summary
§ World leaders in pep.de-‐based intracellular drug delivery
§ Combined with Phylogica’s powerful Drug Discovery technology to develop fully-‐integrated drug development plaTorm
§ Transi.oning from plaTorm to product focussed company
§ Well posi.oned to create mul.ple commercialisa.on opportuni.es.
20
For
per
sona
l use
onl
y
Dr. Paul WaQ Chief Scien7fic Officer Tel: +61 8 9489 7777 Fax: +61 8 9489 7700 Mobile: +61 421 550 213 paulw@phylogica.com
Contact Details
21
www.phylogica.com
Dr. Richard Hopkins Chief Execu7ve Officer Tel: +61 8 9489 7777 Fax: +61 8 9489 7700 Mobile: +61 405 656 868 richardh@phylogica.com
For
per
sona
l use
onl
y
top related